Vaginal misoprostol may leads to higher nausea compared with surgical evacuation of uterus (low certainty).
Vaginal misoprostol may leads to higher diarrhoea compared with surgical evacuation of uterus (low certainty).
Vaginal misoprostol may leads to higher pain relief compared with surgical evacuation of uterus (low certainty).
Vaginal misoprostol showed no clear difference in woman’s satisfaction/acceptability of method compared with surgical evacuation of uterus (low certainty).
The review found no eligible studies for this question.
Vaginal misoprostol showed no clear difference in nausea compared with placebo (low certainty).
Vaginal misoprostol showed no clear difference in diarrhoea compared with placebo (low certainty).
It is very uncertain whether vaginal misoprostol changes blood loss: haemoglobin difference > 10 g/L compared with placebo (very low certainty).
It is very uncertain whether vaginal misoprostol changes pain (opiate use) compared with placebo (very low certainty).
Vaginal misoprostol showed no clear difference in woman’s satisfaction/acceptability of method compared with placebo (low certainty).
Vaginal misoprostol may leads to lower complete miscarriage compared with surgical evacuation of uterus (low certainty).
Vaginal misoprostol showed no clear difference in pelvic infection compared with surgical evacuation of uterus (low certainty).
Taxane‐containing chemotherapy leads to lower overall survival compared with any chemotherapy without taxane (high certainty).
Taxane‐containing chemotherapy leads to lower disease‐free progression compared with any chemotherapy without taxane (high certainty).
Taxane‐containing chemotherapy showed no clear difference in febrile neutropenia compared with any chemotherapy without taxane (moderate certainty).
Taxane‐containing chemotherapy probably leads to higher neuropathy (including grade 3/4 sensory or motor neuropathy, or both) compared with any chemotherapy without taxane (moderate certainty).
Taxane‐containing chemotherapy showed no clear difference in cardiotoxicity (including grade 3/4 and congestive cardiac failure) compared with any chemotherapy without taxane (moderate certainty).
Taxane followed by anthracyclines showed no clear difference in overall survival ( compared with anthracyclines followed by taxane (moderate certainty).